Thiazole compounds useful as inhibitors of protein kinase

A compound of formula I:

• or a pharmaceutically acceptable derivative thereof, wherein:
• R1 is selected from R, halogen, NO2, or TR;
• T is an optionally substituted C1–C4 alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by O, N(R), C(O), S, SO, or SO2;
• each R is independently selected from hydrogen or an optionally substituted C1-6 aliphatic group, wherein:
• two R bound to the same nitrogen atom are optionally taken together with the nitrogen to form a 3–7 membered saturated, partially unsaturated, or fully unsaturated ring having 0–2 heteroatoms, in addition to the nitrogen bound thereto, independently selected from nitrogen, oxygen, or sulfur;
• Ar1 is an optionally substituted phenyl, wherein:
• Ar1 is optionally substituted by one to four substituents selected from the group consisting of:
• (a) one group selected from QR, Ar2, or QAr2;
• and
• (b) up to four R2 groups;
• each Q is independently selected from a valence bond or an optionally substituted C1-6 alkylidene chain, wherein:
• one or two non-adjacent methylene units of Q are optionally and independently replaced by —O—, —S—, —NR—, —C(O)—, —CO2—, —C(O)NR—, —OC(O)NR—, —C(O)C(O)—, —NRC(O)—, NRCO2—, —NRC(O)NR—, —S(O)—, —SO2—, —NRSO2—, —SO2NR—, or —NRSO2NR—;
• each Ar2 is an optionally substituted ring independently selected from:
• (a) a 3–8 membered monocyclic or 8–10 membered bicyclic saturated, partially unsaturated, or aryl ring;
• (b) a 3–7 membered heterocyclic ring having 1–3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• or
• (c) a 5–6 membered monocyclic or 8–10 membered bicyclic heteroaryl ring having 1–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
• Ar2 is optionally substituted by one to four R2 groups;
• and
• each R2 is independently selected from R, halogen, NO2, CN, OR, SR, N(R)2, NRCOR, NRCON(R)2, NRCO2R, C(O)R, CO2R, CON(R)2, OC(O)N(R)2, SOR, SO2R, SO2N(R)2, NRSO2R, NRSO2N(R)2, C(O)C(O)R, or C(O) CH2C(O)R;
• wherein:
• two R2 on adjacent positions on Ar1 or Ar2 are optionally taken together to form a saturated, partially unsaturated, or fully unsaturated 4–6 membered ring having 0–3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
• each said optionally substituted C1-6 aliphatic group or said optionally substituted C1-6 alkylidene group of Q is optionally and independently substituted with —Ro, —ORo, —SRo, 1,2-methylenedioxy, 1,2-ethylenedioxy, phenyl (Ph) optionally substituted with Ro, —O(Ph) optionally substituted with Ro, —CH2(Ph) optionally substituted with Ro, —CH2CH2(Ph), optionally substituted with Ro, —NO2, —CN, —N(Ro)2, —NRoC(O)Ro, —NRoC(O)N(R)o)2, —NRoCO2Ro, —NRoNRoC(O)Ro, —NRoNRoC(O)N(Ro)2, —NRoNRoCO2Ro, —C(O)C(O)Ro, —C(O)CH2C(O)Ro, —CO2Ro, —C(O)Ro, —C(O)N(Ro)2, —OC(O)N(Ro)2, —S(O)2Ro, —SO2N(Ro)2, —S(O)Ro, —NRoSO2N(Ro)2, —NRoSO2Ro, —C(═S)N(Ro)2, —C(═NH)—N(Ro)2, —(CH2)yNHC(O)Ro, ═O, ═S, ═NNHR*, ═NN(R*)2, ═NNHC(O)R*, ═NNHCO2(alkyl), ═NNHSO2(alkyl), or ═NR*;
• each Ro is independently selected from hydrogen, optionally substituted C1-6 aliphatic, an unsubstituted 5–6 membered heteroaryl or heterocyclic ring, phenyl, —O(Ph), or —CH2(Ph), and said optionally substituted C1-6 aliphatic group of Ro is optionally and independently substituted with NH2, NH(C1-4 aliphatic), N(C1-4 aliphatic)2, halogen, C1-4 aliphatic, OH, O(C1-4 aliphatic), NO2, CN, CO2H, CO2H, CO2(C1-4 aliphatic), O(halo C1-4 aliphatic), or halo C1-4 aliphatic;
• each R* is independently selected from hydrogen or an optionally substituted C1-6 aliphatic, and said optionally substituted C1-6 aliphatic group of R* is optionally and independently substituted with NH2, NH(C1-4 aliphatic), N(C1-4 aliphatic)2, halogen, C1-4 aliphatic, OH, O(C1-4 aliphatic), NO2, CN, CO2H, CO2(C1-4 aliphatic), O(halo C1-4 aliphatic), or halo(C1-4 aliphatic);
• provided that two R2 are not simultaneously OR in the meta and para positions of Ar1.